25 new sites approved for Remdesivir production in India
Production capacity of Remdesivir medicine has been ramped up to more than 90 lakhs vials per month.
As many as 25 new manufacturing sites for Remdesivir production have been approved, Union Minister of State for Chemicals and Fertilizers Mansukh Mandaviya said.
The minister said in a series of tweets on Friday that the 25 production sites for Remdesivir were approved on April 12. The antiviral drug is developed by the biopharmaceutical company Gilead Sciences.
"Since 12th April, 25 new manufacturing sites for #Remdesivir's production have been approved," he tweeted.
The minister also said that production capacity of Remdesivir medicine to treat COVID-19 infection has been ramped up to more than 90 lakhs vials per month.
“Production capacity is now ramped up to more than 90 lakhs vials per month, earlier it was 40 lakhs vials/month. Very soon, 3 lakh vial/day will be produced . Monitoring is being done on daily basis. We would not leave any stone unturned to supply Remdesivir,” the minister added.
Remdesivir, an antiviral medication marketed under the brand name Veklury, is one of the drugs used for treating SARS-CoV-2 virus in hospitalised adults. It is administered via injection into a vein. Remdesivir was approved or authorized for emergency use to treat COVID-19 in around 50 countries.